RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.0 million for the first quarter ended March 31, 2010, compared to net sales of $6.0 million for the same period during 2009, an increase of 16%.
The company also reported net earnings of $211,000, or $0.01 per share, during the first quarter of 2010, compared to a net loss of $171,000, or $0.01 per share, during the same quarter in 2009.
"After encountering a tough economic climate in 2009, our international dietary supplements licensee is beginning to see an improving market overseas," said RBC Life Sciences President and CEO John W. Price. "Domestically, we saw an increase in our medical products customer base while we also continued a number of sales and marketing initiatives designed to offset the first quarter decline in our network marketing independent Associate base."
RBC Life Sciences announced recently that it has been certified as being compliant with Good Manufacturing Practices (GMPs) for the dietary supplement industry. The company invested substantial resources to achieve the compliance during 2009 and will continue to do so annually to remain compliant. GMPs ensure that companies adhere to practices that promote product safety, quality and efficacy.
Breakthrough research offers hope for improved treatment of chronic wounds